Shaperon Inc.
Financials
Valuation Metrics
Shaperon Inc.'s Market Cap is ₩236B. At end of 2025 it was ₩805B. Ranked #2241 of 2,421 in KR market (top 93%), #1477 of 1,640 on KOSDAQ (top 90%), #220 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 95%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 23.58B KRW | KR#2,241/2,421 Sec#220/231 |
| Revenue | 322.6M KRW | KR#2,391/2,421 Sec#222/231 |
| Net Income | -15.83B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 29.18B KRW | KR#2,343/2,421 Sec#222/231 |
| Net Assets | 19.03B KRW | KR#2,302/2,421 Sec#215/231 |
| Employees | 54 | KR#2,023/2,421 Sec#185/231 |
| Value | ||
| P/B | 1.24x | KR#1,646/2,421 Sec#112/231 |
| P/S | 73.11x | KR#2,383/2,421 Sec#203/231 |
| FCF Yield | -61.61% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -83.21% | KR#2,331/2,421 Sec#213/231 |
| ROA | -54.26% | KR#2,372/2,421 Sec#218/231 |
| Op. Margin | -4840.89% | KR#2,391/2,421 Sec#222/231 |
| Revenue Growth | 1186.70% | KR#5/2,421 Sec#3/231 |
| Financial Health | ||
| Debt Ratio | 53.35% | KR#1,004/2,421 Sec#117/231 |
| Total Debt | 7.65B KRW | KR#1,703/2,421 Sec#156/231 |
| FCF | -14.53B KRW | KR#1,812/2,421 Sec#167/231 |
| Cash | 991.4M KRW | KR#2,336/2,421 Sec#221/231 |
| Current Ratio | 3.01x | KR#554/2,421 Sec#76/231 |
| Performance | ||
| 1Y Return | -73.94% | KR—/2,421 Sec—/231 |
| 1M Return | 3.87% | KR—/2,421 Sec—/231 |
| From 52W High | -84.96% | KR#2,386/2,421 Sec#227/231 |
| 1Y MDD | -86.16% | KR#2,382/2,421 Sec#228/231 |
| Trading | ||
| Volume | 554,548 shares | KR—/2,421 Sec—/231 |
| Trading Value | 278.7M KRW | KR—/2,421 Sec—/231 |
| Foreign Own. | 5.82% | KR#752/2,421 Sec#69/231 |
| Per Share | ||
| EPS | -342 KRW | KR—/2,421 Sec—/231 |
| BPS | 411 KRW | KR#2,396/2,421 Sec#226/231 |
Company Info
SHAPERON, established in 2008 and listed on KOSDAQ in 2022, is a bio-venture company specializing in new drug candidate development. It expanded its global presence by establishing a U.S. subsidiary in 2023. The company possesses the world's first GPCR19 target-based inflammation inhibitor platform and a nanobody antibody development platform, with various therapeutics in clinical development. SHAPERON is accelerating new drug candidate discovery through an AI-based platform, established after its innovative new drug research center in 2023, and is headquartered in Gangnam-gu, Seoul.